Prevalence of bacterial infections and diseases is especially high in third world countries and significantly hampers quality of life across the globe. Further adding to the woes of the affected population is the increasing strains of bacteria that are resistant to conventional antibacterial drugs.
The epidemic of antibacterial resistance has spurred interest among the global healthcare organizations and a few pharmaceutical companies and research institutes to develop next-generation antibacterial drugs to effectively thwart such maladies. Unregulated and over prescription of antibacterial drugs has led to increased drug resistance. Moreover, genetic mutations are considered to be another major reason for antibacterial drug resistance. Ironically, these factors have greatly constrained the growth of antibacterial drugs market for years.
Prospective drug candidates in research to improve the future outlook of the global antibacterial drugs market
The global antibacterial drugs market potential is estimated based on the current antibacterial drug classes, including those mentioned above and those in clinical trials. As of March 2016, there are around 37 drugs in clinical development for treating serious bacterial infections. These drugs are intended to be primarily launched in the U.S.
Moreover, FDA is encouraging development of new antibacterial drugs by laying out guidelines for the industry on the types of clinical studies to be conducted on antibacterial drug evaluation. This factor coupled with various incentives for research companies would create a positive outlook for the global antibacterial drugs resistance market in the near future.
Also, in March 2017, the WHO released a list of pathogens, classified based on the criticality/urgency, for which newer antibacterial drugs are required. The different environmental forces working towards development of newer antibacterial drugs would be a major continuing factor for the global antibacterial drugs market growth.
Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/177
Alarming rise in drug resistant strains of bacteria driving awareness initiatives and programs by global healthcare organizations to back companies in the antibacterial drugs market
According to the Centers for Drug Disease Prevention and Control (CDC), every year at least 2 million people in the U.S. acquire bacterial infections that are resistant to drugs. Antibacterial resistance results in 23,000 deaths every year in the U.S. Moreover, according to the European Antimicrobial Resistance Surveillance Network (EARS-Net) data of November 2016, antibiotic resistance is higher in southern and south-eastern Europe than in northern Europe.
Some of the major players in the global antibacterial drugs market are Pfizer, Inc., Johnson & Johnson, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Evotec Pharmaceuticals, Allecra Therapeutics, Kyorin Pharmaceutical, and Allergan plc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.